Drugmakers and pharmacists battle over who gets to make obesity drugs
(By Sydney Lupkin for NPR) Ozempic and similar drugs for Type 2 diabetes and weight loss are in such high
Read More(By Sydney Lupkin for NPR) Ozempic and similar drugs for Type 2 diabetes and weight loss are in such high
Read More(By Alexandra Murphy for Becker’s Hospital Review) The FDA has updated the labels for all GLP-1 receptor agonists, including popular
Read More(By Jakob Emerson for Becker’s Hospital Review) In 2023, more than 61% of Ozempic prescriptions went to patients with commercial
Read More(By Rylee Wilson for Becker’s Hospital Review) Premiums for plans on the ACA marketplace will rise 7% on average in
Read More(By Sydney Lupkin for NPR) Jim Cox had heard of people with Type 2 diabetes who were unable to get
Read More(By Tammie Smith for The Kaiser Family Foundation published June 12, 2024) Affordable Care Act (ACA) Marketplace plans rarely cover
Read More(By Tammie Smith at The Kaiser Family Foundation published May 10, 2024) About one in eight adults (12%) say they
Read More(By Juliette Cubanski, Tricia Neuman, Nolan Sroczynski, and Anthony Damico for The Kaiser Family Foundation Published: Apr 24, 2024) The
Read More(By Chris Lee for The Kaiser Family Foundation published March 23, 2024) A KFF analysis shows that gross total Medicare
Read More(By Judith Graham for KFF Health News) Corlee Morris has dieted throughout her adult life. After her weight began climbing
Read More